# Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

> **NCT01745588** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **PROCEDURE:** stem cell
- **DRUG:** Dexamethasone
- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT01745588
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2025-09-03
- **Final completion:** 2025-09-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01745588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01745588, "Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01745588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*